Jubilant Biosys Convenes 2nd EDGE Innovation Forum, Uniting Biotech Founders, Investors, and Pharma Leaders to Accelerate Next-Generation Therapies
核心洞察
Jubilant Biosys (搜索) hosted the 2nd EDGE Innovation Forum in San Diego on July 23, 2026, drawing over 50 organizations including 40 biotech companies and more than 5 large pharma firms.
The Emerging NewCos Showcase featured four biotech startups pitching their therapeutic programs and technology platforms to venture investors and drug discovery experts.
Over 30 C-suite executives attended, with representatives from eight companies participating in two on-stage panel discussions on capital access and partnership models.
Jubilant Biosys (搜索), an integrated drug discovery and development partner, convened the 2nd EDGE Innovation Forum in San Diego on July 23, 2026, bringing together leading biotechnology founders, venture capital leaders, pharmaceutical executives, and drug discovery experts from around the world. The forum, hosted in one of the world's premier biotechnology hubs, aimed to exchange ideas, foster collaboration, and explore pathways to accelerate the development of next-generation therapies.
The event drew over 50 organizations, including 40 biotechnology companies, more than five large pharmaceutical companies, and eight investment firms. Over 30 C-suite executives attended the gathering, underscoring the senior-level commitment to addressing the industry's most pressing challenges.
Addressing the Funding Gap in Drug Discovery
A central theme of the forum was the persistent challenge of securing investment for early-stage discovery programs. Mr. TJ Sigler, Senior Vice President of Business Development at Jubilant Biosys (搜索), captured the sentiment driving the initiative.
"So much of a biotech's success these days depends on its ability to attract investors. While the funding environment appears to be improving, many discovery programs still struggle to secure the investment they need to advance," Sigler said. "Jubilant wanted to create a platform that brings together biotech and venture capital leaders to network, exchange insights, and build meaningful connections, helping innovative ideas ultimately reach patients."
The forum addressed pressing opportunities and challenges shaping the industry, including scientific innovation, capital deployment, and evolving partnership models that are redefining drug discovery and development.
Emerging NewCos Showcase Highlights Breakthrough Science
A highlight of the forum was the Emerging NewCos Showcase, where four selected biotechnology startups presented their therapeutic programs and technology platforms to an audience of venture investors, pharmaceutical leaders, and drug discovery experts. The showcase provided entrepreneurs with opportunities to receive strategic feedback, engage with potential collaborators, and build relationships aimed at advancing breakthrough healthcare technologies.
The event featured a keynote session by Deborah Nguyen, Operating Partner at Red Tree Venture Labs (搜索), alongside startup pitch presentations, expert panel discussions, and curated networking opportunities. Representatives from eight companies participated in two on-stage panels, exploring the future of healthcare innovation and the critical role that partnerships between biotechnology companies, investors, pharmaceutical organizations, and research partners will play in bringing new therapies to patients faster and more efficiently.
Industry Leaders Convene for Meaningful Dialogue
The forum brought together an accomplished group of industry leaders from organizations including Foresite Capital (搜索), Red Tree Venture Labs (搜索), Curie Bio (搜索), LYZZ Capital (搜索), Rezo Therapeutics (搜索), Numerion Labs (搜索), and Jubilant Biosys (搜索). Senior leadership from the Jubilant Bhartia Group and Jubilant Biosys also participated, including Mr. Shantanu Jha, Group CHRO of Jubilant Bhartia Group; Dr. Prasant Deb, Senior Vice President and Site Head for Noida and Greater Noida; Dr. Sreekanth Rouduri, Vice President and Site Head for Bengaluru; and other scientific and business leaders.
Mr. Jay Sheth, Associate Vice President of Business Development and Head of VC Partnerships at Jubilant Biosys (搜索), concluded the event by reinforcing the forum's mission. "In today's biotech environment, innovation requires more than great science. It requires the right combination of capital, execution, and strategic partnerships. Through EDGE, Jubilant is committed to bringing together founders, investors, and industry leaders to accelerate the next generation of biotech breakthroughs."
Building on the momentum of its second edition, EDGE continues to grow as a forum for meaningful conversations between biotech innovators, investors, and drug discovery leaders. Jubilant Biosys (搜索), with more than 20 years of experience, over 1,300 scientists, and operations across India and France, supports small molecule programs from discovery through commercial manufacturing, alongside discovery services for biologics and other advanced therapeutic modalities.